According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “
Separately, Raymond James Financial Inc. raised shares of Natus Medical from a market perform rating to an outperform rating and set a $46.00 target price for the company in a research report on Tuesday, September 13th.
Shares of Natus Medical (NASDAQ:BABY) opened at 39.89 on Wednesday. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of 34.39 and a beta of 0.85. The firm has a 50-day moving average of $40.37 and a 200 day moving average of $36.81. Natus Medical has a one year low of $29.54 and a one year high of $51.05.
Natus Medical (NASDAQ:BABY) last posted its earnings results on Wednesday, July 20th. The company reported $0.39 EPS for the quarter, beating the Zacks’ consensus estimate of $0.36 by $0.03. Natus Medical had a net margin of 10.20% and a return on equity of 13.82%. The company earned $96 million during the quarter, compared to analysts’ expectations of $92.71 million. During the same quarter in the prior year, the company posted $0.34 earnings per share. Natus Medical’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, equities research analysts predict that Natus Medical will post $1.58 EPS for the current year.
In other news, insider James B. Hawkins purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 28th. The shares were bought at an average price of $38.48 per share, for a total transaction of $384,800.00. Following the completion of the transaction, the insider now owns 459,725 shares in the company, valued at $17,690,218. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.80% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC raised its stake in Natus Medical by 39.1% in the second quarter. Acrospire Investment Management LLC now owns 2,844 shares of the company’s stock valued at $108,000 after buying an additional 800 shares in the last quarter. BlackRock Inc. raised its stake in Natus Medical by 36.0% in the second quarter. BlackRock Inc. now owns 3,096 shares of the company’s stock valued at $117,000 after buying an additional 820 shares in the last quarter. Invictus RG purchased a new stake in Natus Medical during the first quarter valued at approximately $148,000. PineBridge Investments L.P. raised its stake in Natus Medical by 3.7% in the second quarter. PineBridge Investments L.P. now owns 4,200 shares of the company’s stock valued at $159,000 after buying an additional 149 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its stake in Natus Medical by 13.9% in the second quarter. Teacher Retirement System of Texas now owns 4,602 shares of the company’s stock valued at $174,000 after buying an additional 562 shares in the last quarter. Institutional investors own 87.92% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.